Cargando…

Real-world Effect of Monoclonal Antibody Treatment in COVID-19 Patients in a Diverse Population in the United States

BACKGROUND: Monoclonal antibodies (mAbs) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are a promising treatment for limiting the progression of coronavirus disease 2019 (COVID-19) and decreasing strain on hospitals. Their use, however, remains limited, particularly in disadva...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rainwater-Lovett, Kaitlin, Redd, John T, Stewart, Miles A, Calles, Natalia Elías, Cluff, Tyler, Fang, Mike, Panaggio, Mark J, Lambrou, Anastasia S, Thornhill, Jonathan K, Bradburne, Christopher, Imbriale, Samuel, Freeman, Jeffrey D, Anderson, Michael, Kadlec, Robert P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Major Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8364980/ https://www.ncbi.nlm.nih.gov/pubmed/34409125 http://dx.doi.org/10.1093/ofid/ofab398

Ejemplares similares

Staffing and Capacity Planning for SARS-CoV-2 Monoclonal Antibody Infusion Facilities: A Performance Estimation Calculator Based on Discrete-Event Simulations
por: Çaglayan, Çaglar, et al.
Publicado: (2022)

Gecko: A time-series model for COVID-19 hospital admission forecasting
por: Panaggio, Mark J., et al.
Publicado: (2022)

Real-world Effectiveness and Tolerability of Monoclonal Antibody Therapy for Ambulatory Patients With Early COVID-19
por: Webb, Brandon J, et al.
Publicado: (2021)

Influenza outbreak control practices and the effectiveness of interventions in long-term care facilities: a systematic review
por: Rainwater-Lovett, Kaitlin, et al.
Publicado: (2014)

Real-world Assessment of 2879 COVID-19 Patients Treated With Monoclonal Antibody Therapy: A Propensity Score–Matched Cohort Study
por: Cooper, Megan H, et al.
Publicado: (2021)

Assessment of Infectious Diseases Risks From Dental Aerosols in Real-World Settings
por: Choudhary, Shruti, et al.
Publicado: (2022)

Strength of Recommendation and Quality of Evidence for Recommendations in Current Infectious Diseases Society of America Guidelines
por: Miles, Kaitlin E, et al.
Publicado: (2021)

Viral Epidemiology: Tracking Viruses with Smartphones and Social Media
por: Rainwater-Lovett, Kaitlin, et al.
Publicado: (2016)

Variation in dengue virus plaque reduction neutralization testing: systematic review and pooled analysis
por: Rainwater-Lovett, Kaitlin, et al.
Publicado: (2012)

Monoclonal Antibody Therapy for COVID-19 in Solid Organ Transplant Recipients
por: Yetmar, Zachary A, et al.
Publicado: (2021)

Detection of foot-and-mouth disease virus infected cattle using infrared thermography
por: Rainwater-Lovett, Kaitlin, et al.
Publicado: (2009)

Comparative Efficacy of Early COVID-19 Monoclonal Antibody Therapies: A Retrospective Analysis
por: San Filippo, Savanna, et al.
Publicado: (2022)

Safety, Tolerability and Pharmacokinetics of Half-Life Extended Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Monoclonal Antibodies AZD7442 (Tixagevimab-Cilgavimab) in Healthy Adults
por: Forte-Soto, Pablo, et al.
Publicado: (2023)

Effectiveness of Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Infusions in High-Risk Outpatients
por: Piccicacco, Nicholas, et al.
Publicado: (2021)

Establishment of Monoclonal Antibody Standards for Quantitative Serological Diagnosis of SARS-CoV-2 in Low-Incidence Settings
por: Thomas, Archana, et al.
Publicado: (2021)

Prototype Pathogen Approach for Vaccine and Monoclonal Antibody Development: A Critical Component of the NIAID Plan for Pandemic Preparedness
por: Cassetti, M Cristina, et al.
Publicado: (2022)

Modeling the Impact of a Highly Potent Plasmodium falciparum Transmission-Blocking Monoclonal Antibody in Areas of Seasonal Malaria Transmission
por: Challenger, Joseph D, et al.
Publicado: (2023)

A Dynamic Transmission Model to Evaluate the Effectiveness of Infection Control Strategies
por: Khader, Karim, et al.
Publicado: (2017)

Safety and Pharmacokinetics of Monoclonal Antibodies VRC07-523LS and PGT121 Administered Subcutaneously for Human Immunodeficiency Virus Prevention
por: Mahomed, Sharana, et al.
Publicado: (2022)

Impact of Bamlanivimab Monoclonal Antibody Treatment on Hospitalization and Mortality Among Nonhospitalized Adults With Severe Acute Respiratory Syndrome Coronavirus 2 Infection
por: Bariola, J Ryan, et al.
Publicado: (2021)

The Dynamics of Infectious Diseases Associated With Injection Drug Use in Lawrence and Lowell, Massachusetts
por: Gonsalves, Gregg S, et al.
Publicado: (2021)

Randomized Clinical Trial to Assess the Impact of the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 on HIV-1 Persistence in Individuals on Effective ART
por: Riddler, Sharon A, et al.
Publicado: (2018)

Performance of a Triage Protocol for Monoclonal Antibodies in a Mixed Vaccinated and Unvaccinated Cohort of COVID-19 Patients Treated With Intravenous Infusion or Subcutaneous Injection
por: Rubin, Emily B, et al.
Publicado: (2022)

A Real-world Multicenter Outpatient Experience of Ceftolozane/Tazobactam
por: Van Anglen, Lucinda J, et al.
Publicado: (2023)

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of the Monoclonal Antibody MHAA4549A in Patients With Acute Uncomplicated Influenza A Infection
por: Lim, Jeremy J, et al.
Publicado: (2021)

Influenza Hospitalizations Among American Indian/Alaska Native People and in the United States General Population
por: Gounder, Prabhu P., et al.
Publicado: (2014)

Cumulative Incidence and Relative Risk of Infection in Patients With Multiple Myeloma Treated With Anti-CD38 Monoclonal Antibody-Based Regimens: A Systematic Review and Meta-analysis
por: Vassilopoulos, Stephanos, et al.
Publicado: (2022)

Effectiveness of Casirivimab-Imdevimab Monoclonal Antibody Treatment Among High-Risk Patients With Severe Acute Respiratory Syndrome Coronavirus 2 B.1.617.2 (Delta Variant) Infection
por: Al-Obaidi, Mohanad M, et al.
Publicado: (2022)

Impact of Procalcitonin-Guided Antibiotic Management on Antibiotic Exposure and Outcomes: Real-world Evidence
por: Broyles, Michael R
Publicado: (2017)

Real-World Experience With Ceftazidime-Avibactam for Multidrug-Resistant Gram-Negative Bacterial Infections
por: Jorgensen, Sarah C J, et al.
Publicado: (2019)

Effectiveness of Dalbavancin Compared With Standard of Care for the Treatment of Osteomyelitis: A Real-world Analysis
por: Cain, Alexander R, et al.
Publicado: (2021)

Real-world Use of Bezlotoxumab and Fecal Microbiota Transplantation for the Treatment of Clostridioides difficile Infection
por: de la Villa, Sofía, et al.
Publicado: (2023)

Temporal Trends of Infective Endocarditis in North America From 2000 to 2017—A Systematic Review
por: Talha, Khawaja M, et al.
Publicado: (2021)

Nasal Spray of Neutralizing Monoclonal Antibody 35B5 Confers Potential Prophylaxis Against Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern: A Small-Scale Clinical Trial
por: Lin, Yao, et al.
Publicado: (2022)

Attitudes towards sub-domains of professionalism in medical education: defining social accountability in the globalizing world
por: Ponka, David, et al.
Publicado: (2017)

A Qualitative Study of the Real-world Experiences of Infectious Diseases Fellows Regarding Antibiotic Stewardship
por: Morgan, Jake R, et al.
Publicado: (2018)

Outpatient Parenteral Therapy for Complicated Staphylococcus aureus Infections: A Snapshot of Processes and Outcomes in the Real World
por: Townsend, Jennifer, et al.
Publicado: (2018)

Real-World Experience With Higher-Than-Recommended Doses of Lamivudine in Patients With Varying Degrees of Renal Impairment
por: Fischetti, Briann, et al.
Publicado: (2018)

Real-world Experience of Bezlotoxumab for Prevention of Clostridioides difficile Infection: A Retrospective Multicenter Cohort Study
por: Hengel, Richard L, et al.
Publicado: (2020)

Real-World Experience of Bamlanivimab for Coronavirus Disease 2019 (COVID-19): A Case-Control Study
por: Kumar, Rebecca N, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_09ip4qsqmj0hgboif1cfj66556